ArticleBlood advances2025
Inaccuracies of venous thromboembolism risk assessment and prevention practices among medically ill patients.
Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluating longitudinal data accuracy in postpartum venous thromboembolism risk assessments: a retrospective observational study.Research and practice in thrombosis and haemostasis · 2026Observational
- Multisite Real-World Validation of an Electronic Health Record-Integrated Generative Artificial Intelligence Tool for Venous Thromboembolism Risk Stratification.medRxiv : the preprint server for health sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractVenous thromboembolism (VTE) is a common cause of preventable harm among hospitalized, medically ill patients. The purpose of this study is to evaluate the accuracy of Padua VTE risk assessments, VTE prevention practices, and outcomes. In this retrospective analysis of consecutively hospitalized, medically ill patients at Johns Hopkins Hospital from 1 January through 30 April 2019, a hematologist subject matter expert (SME) retrospectively completed a Padua VTE risk assessment for every patient. Results were compared with risk assessments completed by the admitting provider. The primary outcome was agreement between the SME and admitting provider on overall VTE risk. Secondary outcomes included agreement on VTE risk factors, risk-appropriate VTE prophylaxis prescription and administration, and VTE outcomes. Of the 4021 patients included, agreement between admitting providers and the SME on overall VTE risk was 65.3%. The SME identified 1156 patients (28.7%) as high risk who were categorized on admission as low risk. Risk factors with the lowest agreement were reduced mobility and acute infection. A total of 2141 patients (53.2%) were prescribed appropriate VTE prophylaxis. Thirty-six patients developed in-hospital VTE, including 21 who had been misclassified as low risk. Significantly more doses of prescribed VTE prophylaxis were not administered among patients who developed VTE (19.6% vs 15.2%; P = .007). Inaccurate VTE risk assessment leads to inappropriate VTE prevention practices and preventable VTE. Leveraging existing structured data to autopopulate VTE risk assessments can assist providers in improving accuracy. Quantitative measures of patient mobility should be incorporated into VTE risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.